DOP2011000081A - Benzamida sustituida como ligandos del receptor de canabinoides - Google Patents

Benzamida sustituida como ligandos del receptor de canabinoides

Info

Publication number
DOP2011000081A
DOP2011000081A DO2011000081A DO2011000081A DOP2011000081A DO P2011000081 A DOP2011000081 A DO P2011000081A DO 2011000081 A DO2011000081 A DO 2011000081A DO 2011000081 A DO2011000081 A DO 2011000081A DO P2011000081 A DOP2011000081 A DO P2011000081A
Authority
DO
Dominican Republic
Prior art keywords
ligands
benzamida
canabinoid
receiver
replaced
Prior art date
Application number
DO2011000081A
Other languages
English (en)
Inventor
William A Carroll
Tongmei Li
Michael J Dart
Jennifer M Frost
Steven P Latshaw
Teodozyi Kolasa
Sridhar Peddi
Bo Liu
Arturo Perez-Medrano
Meena Patel
Xueqing Wang
Derek W Nelson
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41210849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2011000081(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of DOP2011000081A publication Critical patent/DOP2011000081A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)

Abstract

Ligandos de receptores de canabinoides de la fórmula (l) en donde A1, A5, Rx, X4 y z son como se definen en la memoria descriptiva. Se divulgan asímismo composiciones que comprenden dichos compuestos y métodos para el tratamiento de condiciones y trastornos usando dichos com puestos y com posiciones.
DO2011000081A 2008-09-16 2011-03-15 Benzamida sustituida como ligandos del receptor de canabinoides DOP2011000081A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9737808P 2008-09-16 2008-09-16
US22420009P 2009-07-09 2009-07-09

Publications (1)

Publication Number Publication Date
DOP2011000081A true DOP2011000081A (es) 2011-07-15

Family

ID=41210849

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2011000081A DOP2011000081A (es) 2008-09-16 2011-03-15 Benzamida sustituida como ligandos del receptor de canabinoides

Country Status (23)

Country Link
US (2) US8188135B2 (es)
EP (3) EP2334646A2 (es)
JP (1) JP2012502917A (es)
KR (1) KR20110061619A (es)
CN (1) CN102216277A (es)
AR (2) AR073599A1 (es)
AU (1) AU2009293319A1 (es)
BR (1) BRPI0919135A2 (es)
CA (1) CA2737199A1 (es)
CL (1) CL2011000544A1 (es)
CO (1) CO6361998A2 (es)
DO (1) DOP2011000081A (es)
EC (1) ECSP11010974A (es)
ES (1) ES2556752T3 (es)
IL (1) IL211406A0 (es)
MX (1) MX2011002811A (es)
PA (1) PA8842501A1 (es)
PE (1) PE20110804A1 (es)
RU (1) RU2011115087A (es)
TW (1) TW201016692A (es)
UY (1) UY32125A (es)
WO (1) WO2010033543A2 (es)
ZA (1) ZA201101590B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841334B2 (en) * 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
CN102442970A (zh) * 2006-05-31 2012-05-09 雅培制药有限公司 用作大麻素受体配位体的噻唑化合物及其用途
CA2647598A1 (en) * 2006-05-31 2007-12-06 Abbott Laboratories Compounds as cannabinoid receptor ligands and uses thereof
US7875640B2 (en) 2007-03-28 2011-01-25 Abbott Laboratories Compounds as cannabinoid receptor ligands
US7872033B2 (en) 2007-04-17 2011-01-18 Abbott Laboratories Compounds as cannabinoid receptor ligands
EP2160393A1 (en) * 2007-05-18 2010-03-10 Abbott Laboratories Novel compounds as cannabinoid receptor ligands
US9193713B2 (en) * 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
CA2716857A1 (en) 2008-03-11 2009-09-17 Teodozyi Kolasa Novel compounds as cannabinoid receptor ligands
US8846730B2 (en) * 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
BRPI0919135A2 (pt) * 2008-09-16 2015-12-08 Abbott Lab compostos inéditos como ligantes do receptor canabinóide.
PA8854001A1 (es) * 2008-12-16 2010-07-27 Abbott Lab Compuestos novedosos como ligandos de receptores de canabinoides
US8236822B2 (en) 2009-03-27 2012-08-07 Abbott Laboratories Compounds as cannabinoid receptor ligands
US8586596B2 (en) 2010-06-15 2013-11-19 Abbvie Inc. Compounds as cannabinoid receptor ligands
CN103396376B (zh) * 2013-07-31 2016-08-10 杨文茂 一种抗菌抗癌活性化合物
WO2015177063A1 (en) * 2014-05-19 2015-11-26 Syngenta Participations Ag Insecticidally active amide derivatives with sulfur-substituted phenyl or pyridine groups
WO2016066534A1 (en) 2014-10-27 2016-05-06 F. Hoffmann-La Roche Ag Radiolabeled cannabinoid receptor 2 ligand
CN106749078B (zh) * 2015-11-23 2019-01-04 中国科学院大连化学物理研究所 一种2-亚胺基恶唑的合成方法

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1522361A1 (de) 1966-03-08 1969-07-24 Agfa Gevaert Ag Sensibilisierung lichtempfindlicher Polymerer
US3557142A (en) * 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
DE1772867A1 (de) 1968-07-15 1971-06-16 Agfa Gevaert Ag Sensibilisierung von Schichten aus lichtvernetzbaren Polymeren
JPS5089367A (es) * 1973-12-14 1975-07-17
JPS57171986A (en) 1981-04-14 1982-10-22 Taiho Yakuhin Kogyo Kk Heterocylic ring compound containing sulfur
DE3333450A1 (de) * 1983-09-16 1985-04-11 Hoechst Ag, 6230 Frankfurt Trihalogenmethylgruppen enthaltende carbonylmethylenheterocyclen, verfahren zu ihrer herstellung und lichtempfindliches gemisch, das diese verbindungen enthaelt
US4885295A (en) * 1984-08-06 1989-12-05 Sterling Drug Inc. Method of use of 3-arylcarbonyl- and 3-cycloalkyl-carbonyl-1-aminoalkyl-1H-indoles
US4978664A (en) * 1984-08-06 1990-12-18 Sterling Drug Inc. 3-arylcarbonyl- and 3-cycloalkyl-carbonyl-1-aminoalkyl-1H-indole pharmaceutical compositions
DE3533331A1 (de) 1985-09-18 1987-03-26 Heumann Ludwig & Co Gmbh Pyridothiazolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3807381A1 (de) * 1988-03-07 1989-09-21 Hoechst Ag 4,6-bis-trichlormethyl-s-triazin-2-ylgruppen enthaltende heterocyclische verbindungen, verfahren zu ihrer herstellung und lichtempfindliches gemisch, das diese verbindung enthaelt
TW205041B (es) 1989-08-07 1993-05-01 Fujisawa Pharmaceutical Co
DE4021439A1 (de) * 1989-12-14 1991-06-20 Bayer Ag 2-iminopyridin-derivate
US6559186B1 (en) * 1990-02-26 2003-05-06 Arc 1, Inc. Compositions and methods of treatment of sympathetically maintained pain
US5013837A (en) * 1990-03-08 1991-05-07 Sterling Drug Inc. 3-Arylcarbonyl-1H-indole-containing compounds
US4973587A (en) * 1990-03-08 1990-11-27 Sterling Drug Inc. 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method
EP0639569A4 (en) 1991-03-11 1995-09-20 Nippon Soda Co NEW HETEROCYCLIC COMPOUND.
ES2134257T3 (es) * 1992-03-03 1999-10-01 Idemitsu Kosan Co Derivado de pirazol.
DE69319956T2 (de) 1992-04-30 1999-01-14 Hodogaya Chemical Co., Ltd., Tokio/Tokyo Benzothiazolederivate und diese enthaltende fungizide Zusammensetzungen für Landwirtschaft und Gartenbau
US5654322A (en) * 1992-08-11 1997-08-05 Wakunaga Seiyaku Kabushiki Kaisha Biphenylmethane derivatives and pharmaceuticals containing the same
WO1994022821A1 (en) * 1993-04-05 1994-10-13 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives as testosterone 5 alpha-reductase inhibitors
US5395836A (en) 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
JPH06345736A (ja) 1993-06-14 1994-12-20 Tokuyama Soda Co Ltd ウレタン化合物を製造する方法
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
JPH10503171A (ja) 1994-05-17 1998-03-24 ダウエランコ Ｎ−（５−イソチアゾリル）アミド有害生物防除剤
ES2340142T3 (es) 1994-07-08 2010-05-31 Ev3 Inc. Sistema para llevar a cabo un procedimiento intravascular.
FR2735774B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
JPH11512429A (ja) 1995-09-15 1999-10-26 ファルマシア・アンド・アップジョン・カンパニー アミノアリールオキサゾリジノン ｎ−オキシド
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
US6323214B1 (en) * 1997-10-29 2001-11-27 Medco Research, Inc Allosteric adenosine receptor modulators
US6358992B1 (en) * 1998-11-25 2002-03-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with indole derivatives
PT1171437E (pt) 1999-04-20 2004-03-31 Syngenta Ltd Pesticidas derivados de indazole ou benzotriazole
DE19928033A1 (de) 1999-06-18 2000-12-21 Basf Ag Verwendung von cyclischen Enaminen als Lichtschutzmittel
FR2796643B1 (fr) 1999-07-22 2005-04-29 Sod Conseils Rech Applic Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique
GB9918037D0 (en) * 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
DE60011100T2 (de) 1999-08-27 2005-06-16 Abbott Laboratories, Abbott Park Als cox-hemmer verwendbare sulfonylphenylpyrazol-verbindungen
KR100509401B1 (ko) 1999-09-14 2005-08-22 시오노기세이야쿠가부시키가이샤 2-이미노-1,3-티아진 유도체
MXPA02005101A (es) 1999-10-18 2003-09-25 Alexipharma Inc Derivados de indol canabimimeticos.
GB0002032D0 (en) 2000-01-28 2000-03-22 Zeneca Ltd Chemical compounds
GB0002034D0 (en) 2000-01-28 2000-03-22 Zeneca Ltd Chemical compounds
GB0006289D0 (en) * 2000-03-15 2000-05-03 Smithkline Beecham Plc New use
GB0010437D0 (en) 2000-04-28 2000-06-14 Darwin Discovery Ltd Process
CN100369903C (zh) 2000-06-30 2008-02-20 大日本住友制药株式会社 五元环化合物
US6369052B1 (en) * 2000-08-07 2002-04-09 Georgetown University Combination of huperzine and nicotinic compounds as a neuroprotective agent
FR2816938B1 (fr) * 2000-11-22 2003-01-03 Sanofi Synthelabo Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
WO2002060447A1 (en) 2001-01-29 2002-08-08 University Of Connecticut Receptor selective cannabimimetic aminoalkylindoles
WO2002102232A2 (en) 2001-06-14 2002-12-27 The Regents Of The University Of California A novel signaling pathway for the production of inflammatory pain and neuropathy
US7949668B2 (en) * 2001-08-20 2011-05-24 Pardalis, Inc. Common point authoring system for the complex sharing of hierarchically authored data objects in a distribution chain
US20040259912A1 (en) * 2001-09-28 2004-12-23 Takahiro Matsumoto Benzine derivatives, process for preparing the same and use thereof
WO2003037869A1 (en) * 2001-11-01 2003-05-08 Janssen Pharmaceutica N.V. Amide derivatives as glycogen synthase kinase 3-beta inhibitors
US6727247B2 (en) 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives
MXPA04011326A (es) 2002-05-16 2005-02-14 Bayer Cropscience Gmbh Derivados de plaguicidas de piridincarboxamida.
JP3902523B2 (ja) * 2002-08-05 2007-04-11 富士フイルム株式会社 光情報記録媒体および情報記録方法
US20040077617A1 (en) * 2002-10-22 2004-04-22 Bennani Youssef L. Fused cycloalkyl amides and acids and their therapeutic applications
FR2847899B1 (fr) 2002-11-29 2006-04-28 Sanofi Synthelabo Derives d'indole-3-carboxamide, leur preparation et leur application en therapeutique
US7390670B2 (en) * 2003-02-20 2008-06-24 Lumigen, Inc. Signalling compounds and methods for detecting hydrogen peroxide
US20040259887A1 (en) 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US20070105908A1 (en) 2003-06-27 2007-05-10 Dainippon Sumitomo Pharma Co., Ltd. Thiazolimine compound and oxazolimine compound
US6964237B2 (en) 2003-06-30 2005-11-15 Mark P. Hepp Grate block for a refuse incineration grate
EP1670804A2 (en) 2003-09-10 2006-06-21 GPC Biotech AG Heterobicyclic compounds as pharmaceutically active agents
CN100509808C (zh) 2003-12-08 2009-07-08 霍夫曼-拉罗奇有限公司 新型噻唑衍生物
GB0402357D0 (en) 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
DE602004009344T2 (de) 2004-04-19 2008-07-10 Symed Labs Ltd., Hyderabad Neues verfahren zur herstellung von linezolid und verwandten verbindungen
SE0401345D0 (sv) 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine as scaffold
SE0401342D0 (sv) 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds
ATE429423T1 (de) 2004-07-20 2009-05-15 Symed Labs Ltd Neue zwischenprodukte für linezolid und verwandte verbindungen
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
RU2007122351A (ru) 2004-11-15 2008-12-20 Тайсо Фармасьютикал Ко. Иминовое соединение
JP4922946B2 (ja) * 2004-12-21 2012-04-25 アボット・ラボラトリーズ カンナビノイド受容体リガンドとしての３−シクロアルキルカルボニルインドール類
FR2880023B1 (fr) 2004-12-23 2007-02-23 Sanofi Aventis Sa Derives de n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine leur preparation et leur application en therapeutique
US7759337B2 (en) * 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
TW200700387A (en) 2005-03-21 2007-01-01 Akzo Nobel Nv 1-benzylindole-2-carboxamide derivatives
US7674912B2 (en) * 2005-04-25 2010-03-09 H. Lundbeck A/S Pro-drugs of N-thiazol-2-yl-benzamide derivatives
US20070155738A1 (en) * 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
WO2007046550A1 (en) * 2005-10-21 2007-04-26 Mitsubishi Tanabe Pharma Corporation Pyrazole compounds having cannabinoid receptor (cb1) antagonizing activity
AR057987A1 (es) 2005-11-24 2008-01-09 Astrazeneca Ab Compuestos agonistas de cb1 (receptor cannabinoide)
KR100778673B1 (ko) 2005-12-26 2007-11-22 주식회사 포스코 용철 제조 장치
CA2647598A1 (en) * 2006-05-31 2007-12-06 Abbott Laboratories Compounds as cannabinoid receptor ligands and uses thereof
CN102442970A (zh) * 2006-05-31 2012-05-09 雅培制药有限公司 用作大麻素受体配位体的噻唑化合物及其用途
US8841334B2 (en) * 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
US7683084B2 (en) * 2006-06-27 2010-03-23 Abbott Laboratories Thiazoline and oxazoline derivatives and their methods of use
CA2659307A1 (en) * 2006-07-28 2008-01-31 Synthon B.V. Crystalline erlotinib
WO2008028094A1 (en) * 2006-08-31 2008-03-06 Abbott Laboratories Compounds as cb2 cannabinoid receptor ligands
WO2008028093A1 (en) * 2006-08-31 2008-03-06 Abbott Laboratories Compounds as cb2 cannabinoid receptor ligands
US8481574B2 (en) * 2006-10-12 2013-07-09 Abbott Laboratories Compounds as cannabinoid receptor ligands
US8796267B2 (en) * 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
US7793912B2 (en) * 2006-11-08 2010-09-14 Denso Corporation Fluid pressure actuated poppet valve
US9763894B2 (en) * 2006-12-05 2017-09-19 Virginia Commonwealth University Inflammation therapy
TW200831092A (en) * 2006-12-21 2008-08-01 Astrazeneca Ab Therapeutic agents
WO2008079687A1 (en) * 2006-12-22 2008-07-03 Abbott Laboratories Novel compounds as cannabinoid receptor ligands and uses thereof
CA2676944C (en) 2007-02-15 2016-01-19 F. Hoffmann-La Roche Ag 2-aminooxazolines as taar1 ligands
US7875640B2 (en) * 2007-03-28 2011-01-25 Abbott Laboratories Compounds as cannabinoid receptor ligands
US7872033B2 (en) 2007-04-17 2011-01-18 Abbott Laboratories Compounds as cannabinoid receptor ligands
US8501794B2 (en) * 2007-04-17 2013-08-06 Abbvie Inc. Compounds as cannabinoid receptor ligands
EP2148867B1 (en) 2007-04-19 2014-09-10 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
EP2160393A1 (en) * 2007-05-18 2010-03-10 Abbott Laboratories Novel compounds as cannabinoid receptor ligands
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
WO2009035598A1 (en) * 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090088416A1 (en) * 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090137457A1 (en) * 2007-10-02 2009-05-28 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
US9193713B2 (en) * 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
US8410124B2 (en) 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
US8044071B2 (en) * 2007-10-18 2011-10-25 Abbott Laboratories Method for reducing side effects of CB2 receptor agonist therapy using a combination of a selective CB2 receptor agonist and a selective CB1 receptor antagonist
CA2703591C (en) 2007-10-26 2013-05-07 Concert Pharmaceuticals, Inc. Deuterated darunavir
CA2706586A1 (en) 2007-11-21 2009-05-28 Alan S. Florjancic Novel compounds as cannabinoid receptor ligands and uses thereof
CA2716857A1 (en) * 2008-03-11 2009-09-17 Teodozyi Kolasa Novel compounds as cannabinoid receptor ligands
MX2011001755A (es) * 2008-08-15 2011-03-24 Abbott Lab Derivados de imina como ligandos de receptor canabinoide.
US8846730B2 (en) * 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
BRPI0919135A2 (pt) * 2008-09-16 2015-12-08 Abbott Lab compostos inéditos como ligantes do receptor canabinóide.
CN102272111A (zh) 2008-11-04 2011-12-07 雅培制药有限公司 作为大麻素受体配体的1,2-噻唑基衍生物
PA8854001A1 (es) 2008-12-16 2010-07-27 Abbott Lab Compuestos novedosos como ligandos de receptores de canabinoides
EP2411370B1 (en) * 2009-03-27 2015-04-22 AbbVie Inc. Compounds as cannabinoid receptor ligands
US8236822B2 (en) * 2009-03-27 2012-08-07 Abbott Laboratories Compounds as cannabinoid receptor ligands
EP2411382A1 (en) * 2009-03-27 2012-02-01 Abbott Laboratories Compounds as cannabinoid receptor ligands
US8586596B2 (en) * 2010-06-15 2013-11-19 Abbvie Inc. Compounds as cannabinoid receptor ligands

Also Published As

Publication number Publication date
UY32125A (es) 2010-04-30
ECSP11010974A (es) 2011-05-31
WO2010033543A3 (en) 2010-11-18
JP2012502917A (ja) 2012-02-02
CA2737199A1 (en) 2010-03-25
AR073599A1 (es) 2010-11-17
PE20110804A1 (es) 2011-11-30
CO6361998A2 (es) 2012-01-20
US8188135B2 (en) 2012-05-29
CL2011000544A1 (es) 2011-06-17
AR077664A2 (es) 2011-09-14
US8859596B2 (en) 2014-10-14
EP2428507B1 (en) 2015-10-21
EP2428507A3 (en) 2012-06-13
CN102216277A (zh) 2011-10-12
BRPI0919135A2 (pt) 2015-12-08
KR20110061619A (ko) 2011-06-09
WO2010033543A2 (en) 2010-03-25
US20100069349A1 (en) 2010-03-18
PA8842501A1 (es) 2010-04-21
ZA201101590B (en) 2012-08-29
EP2334646A2 (en) 2011-06-22
ES2556752T3 (es) 2016-01-20
AU2009293319A1 (en) 2010-03-25
US20100069348A1 (en) 2010-03-18
TW201016692A (en) 2010-05-01
EP2428507A2 (en) 2012-03-14
MX2011002811A (es) 2011-04-12
RU2011115087A (ru) 2012-10-27
EP2896615A1 (en) 2015-07-22
IL211406A0 (en) 2011-05-31

Similar Documents

Publication Publication Date Title
DOP2011000081A (es) Benzamida sustituida como ligandos del receptor de canabinoides
UY32331A (es) Compuestos novedosos como ligandos de receptores de canabinoides
ECSP10010518A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
CO6341558A2 (es) Antagonistas del recepptor de nmda para el tratamiento de trastornos neuropsiquiatricos
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
TN2011000279A1 (en) Novel pyrazole -4-n-alkoxycarboxamides as microbiocides
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
MA32811B1 (fr) Nouveaux composés
UY31984A (es) DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas.
CO6382157A2 (es) Compuestos pirazina como inhibidores de fosfodiesterasa 10
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
MA32505B1 (fr) 5-alcynyl-pyrimidines
UA103625C2 (en) 5-hetrocyclylalkyl-3-hydroxy-2-phenylcyclopent-2-enons as herbicides
MX2011009780A (es) Pirimidinas sustituidas para el tratamiento del cancer.
TW200942535A (en) Novel compounds as cannabinoid receptor ligands
MX2010005649A (es) Compuestos novedosos como ligandos del receptor canabinoide y sus usos.
MX2010001093A (es) Herbicidas novedosos.
CO6382123A2 (es) Antagonistas de la via hedgehog de ftalazina disustituida
ECSP11010816A (es) Nuevos Compuestos
TN2012000281A1 (en) Mglu2 agonists
CO6341625A2 (es) Derivados de indol como agentes anticáncer
MX2011007266A (es) Microbiocidas nuevos.
UA103197C2 (uk) Застосування ніфуртимоксу для лікування хвороб, спричинених трихомонадами
CL2008001837A1 (es) Uso de compuestos derivados de cinolin-3-carboxamida en el tratamiento de la esquizofrenia.
IN2012DN01223A (es)